Citius Oncology, Inc. received formal notice that the Nasdaq Stock Market LLC granted its request for an extension through April 19, 2027 to evidence…
CITIUS ONCOLOGY, INC. (CTOR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 19, 2026, Citius Oncology, Inc. (the “Company”) received formal notice that the Nasdaq Stock Market LLC (“Nasdaq”) granted its request for an extension through April 19, 2027 (the “Extension Notice”) to evidence compliance with the $1.00 per sha
How this was made
The 30-second read
Why it matters
The filing signals ongoing listing risk; investors may reassess exposure to the stock.
Market read
Primary disclosure of a compliance extension for a micro‑cap biotech, with potential delisting risk.
What to watch
Potential upcoming financing or partnership announcements that could improve share price.
Background
Citius Oncology filed a Form 8‑K reporting Nasdaq's extension of its compliance deadline under Listing Rule 5550(a)(2).
Ticker impact
Nasdaq granted Citius Oncology an extension to meet the $1.00 bid price rule, with delisting risk if compliance is not regained by April 19, 2027.
likely downward pressure as investors price in delisting risk
Primary 8‑K filing, first public disclosure of the extension and its conditions.
Market effects
Limited to small‑cap biotech and Nasdaq Capital Market compliance considerations.
No broader regional effect; impact confined to the issuer.
Minimal global relevance.
Counterpoint
If the company successfully regains compliance before the deadline, the stock could rebound sharply.
Key entities
- companyCitius Oncology, Inc.
Biotech firm listed on Nasdaq Capital Market under ticker CTOR.
- exchangeNasdaq Stock Market LLC
Granted the compliance extension.
